SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

Inclusion Criteria

• •1. Patient aged 18 years or over
• •2. Patient with p16 positive Oropharyngeal squamous cell carcinoma (OPSCC)
• •3. Clinical stage T1-4, N0-3, M0 (stages I-III)
• •4. Any tobacco status
• •5. Life expectancy greater than 36 months
• •6. Positive HPV16 Ct-DNA measured before curative anticancer treatment
• •7. Treated by any curative treatment
• •8. Complete response at 3 months after end of treatment, which means:
• •* Undetectable HPV16 Ct-DNA and no residual disease on imaging (group A) or
• •* Undetectable HPV16 Ct-DNA and suspicious imaging but persistent disease excluded by either biopsy or repeated imaging (group B1) or
• •* Positive HPV16 Ct-DNA and no residual disease on imaging but negative HPV16 Ct-DNA on the subsequent assessment. This second test will be done 1-2 months after the first one (group C1).
• •9. Patient must be affiliated to a Social Security System (or equivalent)
• •10. Patients must have signed a written informed consent form prior to any trial specific procedures. If the patient is physically unable to give his/her written consent, a trusted person of his/her choice, note related to the investigator or the sponsor, can confirm in writing the patient's consent.